SCHEDULE: TD Bank Group Adjusts Stoke Therapeutics Stake

The Toronto-Dominion Bank and TD Securities Inc. have updated their beneficial ownership filing for Stoke Therapeutics, Inc., reporting a combined 4.9% stake.

Summary

• The Toronto-Dominion Bank (TD Bank) and its subsidiary TD Securities Inc. (TDSI) have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Stoke Therapeutics, Inc. common stock.
• TD Bank holds sole voting and dispositive power over 3,173,258 shares, while TDSI holds sole voting and dispositive power over 10,000 shares.
• The total aggregate amount beneficially owned by both entities is 3,183,258 shares, representing 4.9% of the class of securities.
• This filing is an amendment (Amendment No. 2) to a previous filing, with the event date requiring this statement being June 30, 2026.
• Both TD Bank and TDSI are classified as financial institutions (FI), with TD Bank being a 'Bank' and TDSI a 'Broker or dealer'.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new strategic or financial information.

Positives

• The filing confirms continued institutional interest in Stoke Therapeutics, Inc. from a major financial institution.
• The reporting entities are established financial institutions, suggesting a professional and regulated approach to their holdings.

Negatives

• The filing does not provide any new strategic information, financial performance data, or forward-looking guidance for Stoke Therapeutics, Inc.
• The filing is an amendment, indicating a change in ownership rather than a new investment or development.

Risks

• The primary risk associated with this filing is the potential for further changes in beneficial ownership by TD Bank and TDSI, which could impact share price volatility.
• As a financial institution, TD Bank's investment strategy could shift, leading to a reduction or sale of their stake in Stoke Therapeutics, Inc.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Stoke Therapeutics, Inc.'s future performance.

Management Comments

• TD Bank disclaims ownership of the shares reported herein by TDSI except to the extent of its pecuniary interest therein.
• Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, acting as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or is a member of any group with respect to the Issuer or any securities of the Issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and indicate significant, but not controlling, stakes. The presence of TD Bank and TD Securities Inc. reflects the ongoing involvement of large financial entities in the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing may influence investor perception due to the confirmed stake by a major financial institution, but it does not provide new information to directly alter valuations.
• Creditors: No direct impact is indicated as the filing concerns equity ownership, not debt.
• Employees: No direct impact is indicated.

Next Steps

• TD Bank and TD Securities Inc. will continue to monitor their beneficial ownership of Stoke Therapeutics, Inc. common stock.
• Future amendments to this Schedule 13G will be filed if there are material changes in beneficial ownership.

Key Dates

Keywords

Stoke Therapeutics, Schedule 13G, Beneficial Ownership, The Toronto-Dominion Bank, TD Securities Inc., Common Stock, Institutional Investor